Humanin (10mg)

Humanin Peptide

Humanin is a short natural peptide with suggested potential in cell metabolism and inflammation response.⁽³⁾ Researchers have suggested that a mitochondrial genome called ‘16S ribosomal RNA gene’ encodes the Humanin peptide.⁽⁴⁾ Researchers further posit that the peptide’s length may depend on the location of its synthesis. The peptide may contain 21 amino acids if synthesized inside the mitochondria, whereas it may contain 24 amino acids if synthesized outside the mitochondria but inside the cytosol.⁽⁵⁾ Both of these peptides exhibit potential biological activity.

Mitochondria are considered the powerhouses of the cell, and are formed from the engulfment of individual prokaryotes. Eventually, the eukaryotes appear to engulf the prokaryotic (single-celled) organism, and the prokaryotes form an endosymbiotic relationship with the host cell and gradually develop into mitochondria.⁽¹⁾

Mitochondria are considered to be responsible for several vital cellular activities, including energy production, regulation of apoptosis, hemostasis, and formation of heme proteins, among several other functions. All these functions appear to be regulated by mitochondria via their communications to the cell through several retrograde signals. These signals may be encoded by the nuclear genome present in the mitochondria, possibly due to its prokaryotic origin.⁽²⁾

A small peptide called Humanin is derived from this genome. Since this genome appears to play an important role, this peptide has been explored for its potential action in several biological functions.

Overview

The peptide appears to exert potential actions via binding with intracellular molecules and cell membrane receptors, possibly inducing cytoprotective and/or neuroprotective functions.⁽⁹⁾ Researchers suggest that Humanin may bind with the Bcl-2-associated X protein (also called Bax protein). Bax protein is considered to play a vital role in cellular death (apoptosis). Upon binding with the inactive form of the Bax protein, Humanin may inhibit the changes in the Bax protein and potentially thereby prevent cellular apoptosis.⁽⁹⁾

Apart from research into its possible interaction with Bax, Humanin studies suggest the peptide may also bind with other intracellular molecules, such as actinin-4 and phosphoprotein 8, which are both involved in cellular apoptosis. Upon binding with these proteins, Humanin may induce cytoprotective actions. Researchers suggest Humanin may bind with two G protein-coupled peptide receptors, namely FPRL-1 and FPRL-2 receptors, which are considered to be involved with neurological function.⁽⁹⁾ By binding with this receptor, Humanin may potentially prevent amyloid β binding with the FPRL-1 and FPRL-2 receptors, which may mitigate some instances of neurological degradation.

Chemical Makeup

Molecular Formula: C₁₁₉H₂₀₄N₃₄O₃₂S₂
Molecular Weight: 2687.3 g/mol
Other Known Titles: HNGF6A protein

 

Research and Clinical Studies

Humanin Peptide and Mitochondrial Functions

Mitochondria appear to be susceptible to reactive oxygen species (ROS), and the presence of such ROS may reduce its functioning. Studies in Humanin mechanisms of action suggest that the peptide may inhibit these reactive oxygen species to some degree, thereby mitigating mitochondria degeneration.⁽¹⁰⁾ One study was produced wherein the researchers attempted to explore the peptide’s action on retinal pigment epithelial cells. These cells were isolated and introduced to tert-butyl hydroperoxide to exert oxidative stress in the cells. Some of these cells were then presented with Humanin peptide for 24 hours. When examined, the cells exposed to Humanin reportedly inhibited the formation of tert-butyl hydroperoxide-induced reactive oxygen species. The researchers suggested the peptide may have restored the bioenergetics in the retinal pigment epithelial cells and increased the functioning of mitochondria.

Humanin Peptide and Cellular Longevity

Studies⁽¹¹⁾ were conducted on several murine models to determine the relation between Humanin with growth hormone (GH) and immunoglobulin (IGF-1). In GH-transgenic murine models, the levels of growth hormone and IGF-1 appeared to be extremely high, which the researchers suggested led to increased body size, accelerated cell aging, and reduced life span. Researchers reported that the levels of Humanin naturally present in the murine models were extremely low, about 70% lower than the control.

Another set of murine models had undetectable levels of GH and IGF-1, along with a reported 40% increase in the Humanin levels. These murine models showed an increased life span compared to normal murine models. These results supported the researchers’ hypothesis that Humanin may be negatively correlated to GH and IGF-1 levels and directly correlated to cellular longevity.

Humanin Peptide and Neurological Deterioration

A study⁽¹²⁾ was conducted on 9-month-old murine models, all of which reportedly possessed high levels of amyloid proteins. These amyloid chemicals are indicative of some neurological deterioration. Some murine models were presented with Humanin, while others were given a placebo. Following the study, the researchers suggested that the placebo models showed impaired memory and poor learning skills. In contrast, the murine models presented with Humanin for 3 months reportedly exhibited significantly improved learning ability and enhanced memory.

In another study,⁽¹³⁾ murine models with experimentally induced impairment in neurological functioning were exposed to Humanin and a similarly structured peptide, PAGA, to determine the potential of both peptides on the brain function of the murine models. Both the peptides showed some modest improvement in the impairment of the brain, as suggested by the researchers.

Another study explored the potential neuroprotective action of Humanin on neurotoxicities induced by Calyculin A in cortical neurons as a model of exposure to neurotoxins. The researchers focused on the potential capability of the peptide to safeguard cortical neurons from Calyculin A-induced neurotoxic action. In this investigation, cortical neurons were preincubated with Humanin to examine its protective role against neurotoxicity. The methodologies utilized in this research included employing 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), lactate dehydrogenase (LDH), and Calcein-AM assays to evaluate the extent of neural damage. Furthermore, caspase 3 signaling and TUNEL assays were conducted to assess neural apoptosis. The study also used Western blot analysis to detect potential expressions of phosphorylated tau, a protein associated with neurodegenerative diseases. Additionally, the study measured the apparent contents of malondialdehyde (MDA) and superoxide dismutase (SOD), and the activity of protein phosphatase 2A (PP2A), which are potential indicators of oxidative stress in neurons.

The results from these investigations posited that preincubation with Humanin may preserve cell viability and potentially protect neurons from Calyculin A-induced damage. Notably, the peptide appeared to alleviate oxidative stress in the neurons and preserved the activity of PP2A, an enzyme involved in dephosphorylating tau proteins. Humanin also may have inhibited the over-phosphorylation of tau at specific sites (Ser199/202, Ser396, and Thr231), which are considered critical to the pathological changes observed in neurodegenerative diseases. From these findings, it was inferred that Humanin potentially offered protective action against neurotoxicities induced by harmful agents like Calyculin A.⁽¹⁴⁾

Humanin Peptide and Insulin Resistance

To determine the potential of Humanin on insulin resistance, a study⁽¹⁵⁾ was conducted on nonobese diabetic murine models. When a group of these models were presented with Humanin, it appeared to restore to some degree the levels of glucose tolerance within 6 weeks. Furthermore, Humanin also potentially delayed the onset of diabetes in the murine models presented with the peptide for 20 weeks. Researchers suggested that following the study results, Humanin may exhibit some action in insulin resistance.

In another study,⁽¹⁶⁾ 12-week-old murine models were subjected to a 60% high-fat diet and were presented with Humanin for 4 weeks. After the study, there appeared to be no difference in the food intake. However, the weight gain had reportedly been reduced by about 20%. Furthermore, there appeared to be a high expenditure of energy, decreased fasting glucose levels, and increased insulin levels.

Another study also explored the potential role of Humanin in influencing insulin sensitivity. The investigation suggested that continuous exposure of Humanin to the central nervous system of murine models appeared to enhance overall insulin sensitivity. This improvement in insulin action seemed to be linked to the activation of STAT-3 (Signal Transducer and Activator of Transcription 3) signaling within the hypothalamus. However, this action was negated when hypothalamic STAT-3 was co-inhibited, suggesting a potential role of this signaling pathway in mediating Humanin actions on insulin sensitivity. Furthermore, centrally-acting Humanin also appeared to improve insulin resistance in peripheral tissues such as liver cells. Ultimately, this appeared to result in reduced blood glucose levels in the murine models.⁽¹⁷⁾

Humanin Peptide and Hypoxia

A study⁽¹⁸⁾ was conducted in which the isolated retinal cells were exposed to cobalt chloride, which appeared to induce hypoxia, leading to cell apoptosis. When the hypoxia-induced cells were presented with Humanin, researchers reported that the peptide appeared to reverse the impact of cobalt chloride and protect the cell from reduced oxygen levels.

Additional studies ⁽¹⁹⁾ have suggested that Humanin may possibly increase metabolic activity and, thereby, cell survival rates in the event of lymphocyte death, which has some implications in ischemia.

Humanin Peptide and Ischemia

This study⁽²⁰⁾ was conducted to further examine the neuroprotective potential of Humanin in the presence of cerebral ischemia. In this study, murine models were experimentally induced with cerebral artery occlusion. Murine models were presented with low concentrations of Humanin for 30 minutes and then, following the procedure, were reintroduced to Humanin at 0, 2, 4, and 6 hours after ischemia. Other murine models were solely presented with Humanin one hour before ischemia. It was suggested that continual introduction to the peptide appeared to reduce the ischemia volume by almost 30%. Humanin presence following ischemia reportedly further reduced the ischemic impact.

Another study on Humanin investigating its potential in mitigating ischemia in cells suggests that the peptide may be capable of reducing infarct size in murine models.⁽²¹⁾ In this notable study, researchers suggested that Humanin may exhibit a potential to significantly reduce infarct size by 41% in a large animal model when introduced alongside standard reperfusion intervention after an ischemic period of 60 minutes, followed by 48 hours of reperfusion. However, it is important to note that the beneficial action of Humanin was not observed when the ischemic period was extended to 75 minutes, followed by the same duration of reperfusion, highlighting a potentially critical window for Humanin. The study also highlights that Humanin has been implicated in various protective roles across multiple organs, attributed to the potential to modulate oxidative stress, regulate insulin sensitivity, and inhibit apoptotic signaling, among other actions.

Humanin Peptide Additional Studies

Studies⁽²²⁾ have suggested that Humanin may bind with the FPR2 receptor in the brain, producing possible anxiolytic action. Consequently, the researchers of this study suggested that Humanin may potentially reduce anxiety symptoms.

In this study,⁽²³⁾ murine carcinogenesis models were exposed twice weekly with an antineoplastic agent (used in cancer cases) and Humanin to explore their potential impact on the carcinogenic cells. While the control agent appeared to induce cell apoptosis, the combination of Humanin and the agent exhibited some potential, somewhat reversing the apoptosis of the healthy cells.